» Articles » PMID: 24895841

National Trends and Inpatient Outcomes of Inflammatory Bowel Disease Patients with Concomitant Chronic Liver Disease

Overview
Publisher Informa Healthcare
Specialty Gastroenterology
Date 2014 Jun 5
PMID 24895841
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There is little information on the frequency of chronic liver disease among hospitalized patients with inflammatory bowel disease (IBD). In this study, we seek to define the common etiologies contributing to chronic liver disease among IBD patients and to identify potential risk factors predictive of increased mortality in this population.

Methods: We analyzed the Nationwide Inpatient Sample from 1988 to 2006 to determine the frequency of chronic liver disease among patients with IBD and to determine their in-hospital outcomes.

Results: From 1988 to 2006, the age-adjusted rate of chronic liver disease among hospitalized patients with IBD has increased from 4.35 per 100,000 persons in 1988-2001 to 7.45 per 100,000 persons in 2004-2006. The most common etiologies contributing to chronic liver disease among IBD patients were: primary sclerosing cholangitis, unspecified chronic hepatitis, chronic hepatitis C, and nonalcoholic fatty liver disease. Compared to IBD patients without liver disease, there was more than a twofold higher rate of inpatient morality among IBD patients with concomitant liver disease (2.7% vs. 1.3%, p < 0.01). The multivariate analysis showed that factors predictive of inpatient mortality include age >50, spontaneous bacterial peritonitis, ascites, hepatic encephalopathy, presence of cirrhosis, malnutrition, Clostridium difficile colitis, and hospital-acquired pneumonia.

Conclusion: There is a higher rate of inpatient mortality among patients with concomitant IBD and chronic liver disease compared to IBD alone. Early recognition and management of complications related to portal hypertension among patients with IBD and chronic liver disease is particularly important in order to reduce inpatient mortality and morbidity.

Citing Articles

Ultrasound Prevalence and Clinical Features of Nonalcoholic Fatty Liver Disease in Patients with Inflammatory Bowel Diseases: A Real-Life Cross-Sectional Study.

Abenavoli L, Spagnuolo R, Scarlata G, Scarpellini E, Boccuto L, Luzza F Medicina (Kaunas). 2023; 59(11).

PMID: 38003983 PMC: 10673463. DOI: 10.3390/medicina59111935.


Systematic Review and Meta-Analysis: Prevalence of Non-Alcoholic Fatty Liver Disease and Liver Fibrosis in Patients with Inflammatory Bowel Disease.

Navarro P, Gutierrez-Ramirez L, Tejera-Munoz A, Arias A, Lucendo A Nutrients. 2023; 15(21).

PMID: 37960160 PMC: 10648917. DOI: 10.3390/nu15214507.


Hepatobiliary manifestations in inflammatory bowel disease: A practical approach.

Nunez F P, Castro F, Mezzano G, Quera R, Diaz D, Castro L World J Hepatol. 2022; 14(2):319-337.

PMID: 35317174 PMC: 8891676. DOI: 10.4254/wjh.v14.i2.319.


The Other Side of Malnutrition in Inflammatory Bowel Disease (IBD): Non-Alcoholic Fatty Liver Disease.

Gibiino G, Sartini A, Gitto S, Binda C, Sbrancia M, Coluccio C Nutrients. 2021; 13(8).

PMID: 34444932 PMC: 8398715. DOI: 10.3390/nu13082772.


Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Lin A, Roth H, Anyane-Yeboa A, Rubin D, Paul S Inflamm Bowel Dis. 2020; 27(6):947-955.

PMID: 32780094 PMC: 8600033. DOI: 10.1093/ibd/izaa189.